A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema

NCT ID: NCT04957641

Last Updated: 2023-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

221 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-21

Study Completion Date

2023-01-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is about teenagers and adults with hereditary angioedema (HAE) type I and type II. In this study, the burden of illness means the impact of HAE in terms of long-term health outcomes and the financial cost.

The main aims of this study are as follows:

* to learn how often, how severe and where on the body HAE attacks occur.
* to describe how HAE prophylaxis and on-demand medicines are prescribed and used. (Prophylaxis medicines prevent a bleed from happening and on-demand medicines treat a bleed when it occurs.)

This study is about collecting data only; participants will not receive treatment as part of this study. Existing data available in the participant's medical records will be collected. Participants will be asked to complete an electronic questionnaire either on a website or by using an app on their mobile phone; data from this questionnaire will also be collected.

Participants do not need to visit their doctor in addition to their normal visits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary Angioedema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with HAE

Participants' data will be collected retrospectively from electronic medical records using chart review of de-identified data on participant demographics, HAE medical history and information on diagnostics, treatments and disease course assessments that are routinely performed in accordance with current guidelines and/or local standard of care which are entered into an Electronic data capture (EDC) system over multiple data collection waves up to 6 months.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant aged \>= 12 years at the time of the last documented HAE attack in the eligibility period.
* Physician-confirmed diagnosis (or confirmation in medical records) of HAE type I or type II.
* Participant had at least one documented HAE attack during the eligibility period.
* Participant is not adequately or sub-optimally controlled according to treating physician.
* Participant (or parent/legal guardian) is willing and able to comply with the study requirements and provides informed consent or assent.

Exclusion Criteria

* Participant enrolled in a therapeutic investigational drug or device trial during the observation period.
* Participant initiated long-term prophylaxis with Takhzyro® at any time since diagnosis.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Takeda

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medizinische Universitat Wien (Medical University of Vienna)

Vienna, , Austria

Site Status

UZ Antwerpen

Edegem, , Belgium

Site Status

University Multiprofile Hospital for Active Treatment Aleksandrovska EAD

Sofia, , Bulgaria

Site Status

Vancouver Allergy Clinic

Vancouver, British Columbia, Canada

Site Status

McMaster University Medical Centre

Hamilton, , Canada

Site Status

General Hospital Sibenik

Šibenik, , Croatia

Site Status

Klinicki bolnicki centar Zagreb

Zagreb, , Croatia

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Fakultni nemocnice v Motole

Prague, , Czechia

Site Status

East Tallinn Central Hospital

Tallinn, , Estonia

Site Status

Universitätsklinikum Frankfurt

Frankfurt, , Germany

Site Status

Navy Hospital of Athens

Athens, , Greece

Site Status

Laiko General Hospital of Athens

Athens, , Greece

Site Status

University General Hospital of Larissa

Larissa, , Greece

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

St James's Hospital

Dublin, , Ireland

Site Status

Barzilai Medical Center

Ashkelon, , Israel

Site Status

Bnai Zion Medical Center

Haifa, , Israel

Site Status

Sheba Medical Center - PPDS

Ramat Gan, , Israel

Site Status

Tel Aviv Sourasky Medical Center PPDS

Tel Aviv, , Israel

Site Status

Pauls Stradins Clinical University Hospital

Riga, , Latvia

Site Status

Centre of Investigation and Treatment of Allergic Diseases

Riga, , Latvia

Site Status

Hospital of Lithuanian University of Health Sciences Kauno klinikos

Kaunas, , Lithuania

Site Status

Vilnius University Hospital Santaros Klinikos

Vilnius, , Lithuania

Site Status

Medical Faculty of Ss. Cyril and Methodius Univers

Skopje, , North Macedonia

Site Status

Wojskowy Instytut Medyczny

Warsaw, , Poland

Site Status

Centro Hospitalar E Universitário de Coimbra EPE

Coimbra, , Portugal

Site Status

Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria

Lisbon, , Portugal

Site Status

Centro Hospitalar de São João, E.P.E.

Porto, , Portugal

Site Status

MediQuest Clinical Research Center

Sângeorgiu de Mures, , Romania

Site Status

University Clinical Center of Serbia - PPDS

Belgrade, , Serbia

Site Status

Univerzitna nemocnica Martin

Martin, , Slovakia

Site Status

Bolnisnica Golnik - Klinicni Oddelek za Pljucne Bolezni In Alergijo

Golnik, , Slovenia

Site Status

Hospital Universitario Cruces

Barakaldo, , Spain

Site Status

Hospital Universitario Vall d'Hebron - PPDS

Barcelona, , Spain

Site Status

Hospital Universitari i Politecnic La Fe de Valencia

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Bulgaria Canada Croatia Czechia Estonia Germany Greece Hungary Ireland Israel Latvia Lithuania North Macedonia Poland Portugal Romania Serbia Slovakia Slovenia Spain

References

Explore related publications, articles, or registry entries linked to this study.

Farkas H, Aygoren-Pursun E, Ebo DG, Bara N, Psarros F, Gavini F, Bent-Ennakhil N, Sayegh L, Andresen I. Real-world treatment patterns and burden-of-disease of sub-optimally controlled hereditary angioedema. World Allergy Organ J. 2025 Sep 1;18(9):101100. doi: 10.1016/j.waojou.2025.101100. eCollection 2025 Sep.

Reference Type DERIVED
PMID: 40949786 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://clinicaltrials.takeda.com/study-detail/60f13b09f883ca001e82d334

To obtain more information on the study, click here/on this link

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MACS-2020-080401

Identifier Type: OTHER

Identifier Source: secondary_id

TAK-743-4009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.